Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Losartan (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms STOP-NAFLD
- 31 Aug 2018 Biomarkers information updated
- 22 Aug 2018 Planned initiation date changed from 16 Jun 2018 to 31 Aug 2018.
- 22 Aug 2018 Status changed from not yet recruiting to recruiting.